Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Capital Bancorp is a bank holding company. Through its subsidiary, Capital Bank, N.A. (the Bank), the company is principally engaged in the business of investing in commercial, real estate, and credit card loans and accepting deposits in Rockville, Columbia and North Bethesda, MD, Reston, VA, and the District of Columbia. The Bank operates three divisions: Commercial Banking, which provides commercial and industrial, commercial real estate and construction lending solutions; Church Street Mortgage, which originates conventional and government-guaranteed residential mortgage loans; and OpenSky?, which provides credit cards to under-banked populations and those looking to rebuild their credit scores.

Cincinnati Financial is a holding company. Through its subsidiaries, the company is engaged in property casualty insurance. The company's market property casualty insurance group includes its subsidiaries, The Cincinnati Casualty Company and The Cincinnati Indemnity Company, which write business, homeowner and auto policies. The company's subsidiary, The Cincinnati Insurance Company conducts the business of the company's reinsurance assumed operations. Other subsidiaries include: The Cincinnati Life Insurance Company, which provides life insurance policies and fixed annuities; and The Cincinnati Specialty Underwriters Insurance Company, which provides excess and surplus lines insurance products.

Community Health Systems is a holding company. Through its subsidiaries, the company operates general acute care hospitals and outpatient facilities. The company provides healthcare services through the hospitals that it owns and operates and affiliated businesses in non-urban and selected urban markets. Services provided through the company's hospitals and affiliated businesses include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric and rehabilitation services. The company also provides additional outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers.

Neogen develops, manufactures, and markets a line of products for food and animal safety. The company's segments are: Food Safety, which is engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; and Animal Safety, which is engaged in the development, production and marketing of products dedicated to animal safety, including a range of consumable products marketed to veterinarians and animal health product distributors, and provides genomic identification and related interpretive bioinformatic services.

Tela Bio is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which the company refers to as a reinforced tissue matrix. The company serves customers in the United States.

Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract.